Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Le Kremlin-Bicetre – page 43

3 418 clinical trials in Le Kremlin-Bicetre, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Le Kremlin-Bicetre at a glance
3 418
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 418 trials in Le Kremlin-Bicetre

Open in trial search

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Study of ONO-4578 and nivolumab with drug combination for first-line treatment in patients with PD-L1 positive advanced colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Ono Pharmaceutical Co. Ltd.

Study of Gallium (68Ga) edotreotide, Fluorocholine (18F) and Fludeoxyglucose (18F) PET imaging for detection and staging of liver cancer and gastro-entero-pancreatic tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorocholine (18F)
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Study of SAR444336 in Adults with Microscopic Colitis Who Achieved Clinical Remission with Budesonide Treatment

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:SAR444336
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione GONO G.I.

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:GHZ339
  • Sponsor:Novartis Pharma AG

Vitiligo

Recruiting

Study of Ritlecitinib Combined with Narrow Band UVB Light Therapy Compared to Ritlecitinib Alone in Adults with Vitiligo

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ritlecitinib
  • Sponsor:Centre Hospitalier Universitaire De Nice

Myocarditis

Recruiting

Study of anakinra compared to placebo for treating acute myocarditis in children admitted to intensive care units

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Anakinra
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study comparing ALG-000184 with tenofovir disoproxil in untreated adults with chronic hepatitis B virus infection

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ALG-000184
  • Sponsor:Aligos Therapeutics Inc.

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Le Kremlin-Bicetre

What the registry says about research in the country

01 Bacterial Infections and Mycoses

Research in this area focuses on bacterial infections, especially severe ear, nose and throat diseases such as idiopathic purulent oedematous sinusitis in adults. The trials are aimed at evaluating whether treatment can improve symptoms and overall patient well-being.

  • Testing a treatment approach for persistent sinus infection
  • Assessing improvement in quality of life over time

In Kremlin Bicêtre, this work reflects a practical effort to better manage chronic ENT infection-related complaints.

02 Cardiovascular Diseases

Clinical research here also covers cardiovascular disease in patients hospitalized for septic shock with tachycardia and hypercontractility. The main goal is to evaluate whether controlling heart rate may help improve survival and clinical outcomes.

  • Studying a heart-rate-lowering strategy in septic shock
  • Comparing outcomes against standard care

These trials are designed to clarify whether better cardiovascular support can reduce risk in critically ill patients.

03 Otorhinolaryngologic Diseases

Another key research focus is otorhinolaryngology, with attention on sinusitis and related ENT disorders. The studies are looking at treatment effectiveness and changes in patient-reported symptoms during follow-up.

  • Measuring symptom relief in sinus disease
  • Tracking changes in disease-specific quality of life

This area highlights efforts to improve everyday functioning for patients living with ongoing nasal and sinus problems.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.